CE | Abdominal | MRI | Amplifier Partner

Description of use

Pi™ software has the following expected clinical benefits:

  • Identify patients not at risk of csPCa (clinically significant prostate cancer) through provision of a risk score that can be considered as part of the decision to biopsy.
  • Find more significant cancer, by highlighting high-risk lesions that radiologists might miss, enabling more accurate targeting.
  • Speed up the process, by facilitating assessment and segmentation tasks through provision of candidate prostate and lesion segmentations.
  • Identify estimated volume of prostate and lesions.

Additional benefits including assisting with teaching non-experienced radiologists how to report prostate MRI, and reducing clinical workload by automating volume calculation and structured reporting.

The application content is provided by the respective AI vendors.